Treatment selection for patients with metastatic renal cell carcinoma

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2327-2333

  Atkins, Michael B ^a,b   Choueiri, Toni K ^b,c   Cho, Daniel ^a,b   Regan, Meredith ^b,c   Signoretti, Sabina ^b,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiangiogenic therapy; Immunotherapy; Inhibitors; Renal cell carcinoma; Target of rapamycin (TOR); Treatment selection

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WILD TYPE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 65949107302     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24231     Document Type: Conference Paper

References (39)

1. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
2. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
3. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883-1887. (Pubitemid 47538608)
4. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141. (Pubitemid 41702632)
5. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
6. Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol. 2008;26(suppl):LBA5026.
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
9. Szczylik C, Demkow, T, Staehler, M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract]. J Clin Oncol. 2007;25(18 suppl pt I). Abstract 5025.
10. Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res. 2004;64:4117-4121. (Pubitemid 38802413)
11. Yang JC, Sherry RM, Stienberg SM, et al. A 3-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol. 2003;21:3127.
12. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother. 2005;28:488-495.
13. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
14. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381.
15. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004;23:5624-5631.
16. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
17. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721. (Pubitemid 40685588)
18. Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol. 2005;23(16 suppl pt 1). Abstract 4535.
19. Jaeger E, Waldman F, Roydasgupta R, et al. Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between interleukin-2 complete and non-responders [abstract]. J Clin Oncol. 2008;26(15 suppl). Abstract 5043.
20. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol. 2007;25(18 suppl): 5033.
21. Plantade A, Choueiri B, Escudier B, et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol. 2007;25(18 suppl): 5037.
22. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122-127. (Pubitemid 43050086)
23. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
24. Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5:379-385. (Pubitemid 47584475)
25. Figlin RA, De Souza P, McDermott D, et al. Analysis of pten and hif1-a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, April 12-16, 2008. Abstract 4477.
26. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio- Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res. 2005;11:4338-4340.
27. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189-3199. (Pubitemid 38638830)
28. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors [abstract]. J Clin Oncol. 2007;25(suppl). Abstract 5024.
29. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543-550.
30. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol. 2007;25. Abstract 5023.
31. Escudier B, Ravaud A, Negrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [abstract]. J Clin Oncol. 2008;26. Abstract 5025.
32. DePrimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol. 2007;18(suppl 10):x11-x19.
33. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32.
34. Hutson T, Davis ID, Macheils JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor [abstract]. J Clin Oncol. 2008;26. Abstract 5046.
35. Rini BI, Michaelson D, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743-3748.
36. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388-7393.
37. Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2008;26. Abstract 5008.
38. Choueiri TK, Vaziri SA, Rini BI, et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2007;25. Abstract 5012.
39. Gad S, Sultan-Amar V, Meric J, et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Targeted Oncol. 2007;2:3-6.